Skip to content

Study · In vitro (cells) · 2001

5 results

Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.

Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A

The Journal of clinical endocrinology and metabolism1 Jul 2001Cited by 57 (Europe PMC)

PMID11443154 (opens in a new tab)DOI10.1210/jcem.86.7.7620 (opens in a new tab)PepBankPUB-11443154
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human somatotroph tumour cultures, lanreotide significantly inhibited cell proliferation in 7 tumors.

    In plain wordsIn lab tests, lanreotide significantly reduced cell proliferation in seven human pituitary tumours.

    Peptide
    Lanreotide
    Outcome
    DecreaseTumour cell proliferation
    Study

    humann = 18

    Primary cultures of somatotroph pituitary adenomas
    Outcome group
    Tumor growth · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our results showed that cell proliferation was significantly inhibited by SST-14, lanreotide, BIM-23190, and BIM-23268 in 4, 7, 3, and 4 tumors, respectively (range of proliferation suppression 5-60%; median, 16%).
    1 context sentence
    Summary · context
    We investigated the effects of SST-14, lanreotide, and SSTR 2 (BIM-23190) and SSTR 5 (BIM-23268) specific analogs in 18 somatotroph pituitary adenomas in primary culture.
  2. 02LabIn vitro (cells)Efficacy outcome

    In human somatotroph tumour cultures, lanreotide inhibited GH secretion in six tumors.

    In plain wordsIn lab tests, lanreotide reduced growth hormone release in six human pituitary tumours.

    Peptide
    Lanreotide
    Outcome
    DecreaseGH secretion
    Study

    humann: not reported in source

    Primary cultures of somatotroph pituitary adenomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SST-14 inhibited GH secretion in 8 of 13 tumors; lanreotide, BIM-23190, and BIM-23268 inhibited GH secretion in six tumors each (range of GH secretion inhibition 23-43%; median 33%).
    1 context sentence
    Summary · context
    We investigated the effects of SST-14, lanreotide, and SSTR 2 (BIM-23190) and SSTR 5 (BIM-23268) specific analogs in 18 somatotroph pituitary adenomas in primary culture.
  3. 03LabIn vitro (cells)Mechanism

    In human somatotroph tumours, lanreotide effects on cell proliferation dissociated from effects on GH secretion.

    In plain wordsIn lab tests, lanreotide effects on tumour cell growth differed from its effects on growth hormone release.

    Peptide
    Lanreotide
    Outcome
    Not applicableProliferation and GH secretion dissociation
    Study

    humann: not reported in source

    Primary cultures of somatotroph pituitary adenomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We observed a dissociation between the in vitro effects of SST-14 or lanreotide on tumor cell proliferation and the effects on GH secretion in human somatotroph tumors.
    1 context sentence
    Summary · context
    We investigated the effects of SST-14, lanreotide, and SSTR 2 (BIM-23190) and SSTR 5 (BIM-23268) specific analogs in 18 somatotroph pituitary adenomas in primary culture.
  4. 04LabIn vitro (cells)Mechanism

    In human somatotroph tumour cultures, tumours responsive to SSTR 2- and 5-specific analogues also responded to lanreotide.

    In plain wordsIn lab tests, tumours responsive to receptor-specific analogues also responded to lanreotide.

    Peptide
    Lanreotide
    Outcome
    Not applicableResponse to receptor-specific analogues and lanreotide
    Study

    humann: not reported in source

    Primary cultures of somatotroph pituitary adenomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tumors that were responsive to SSTR 2- and 5-specific analogs were also responsive to lanreotide.
    1 context sentence
    Summary · context
    We investigated the effects of SST-14, lanreotide, and SSTR 2 (BIM-23190) and SSTR 5 (BIM-23268) specific analogs in 18 somatotroph pituitary adenomas in primary culture.
  5. 05LabIn vitro (cells)Mechanism

    In human somatotroph tumour cultures, SSTR 2 and/or 5 presence did not predict antiproliferative responses to the tested somatostatin analogues, including lanreotide.

    In plain wordsIn lab tests, receptor presence did not predict responses to the tested analogues, including lanreotide.

    Peptide
    Lanreotide
    Outcome
    No significant changePredictive value of SSTR 2 or 5 presence
    Study

    humann: not reported in source

    Primary cultures of somatotroph pituitary adenomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although differences in receptor concentration and the presence of other SST receptor subtypes may play a role, the presence of SSTR 2 and/or 5 did not have a predictive value.
    1 context sentence
    Summary · context
    We investigated the effects of SST-14, lanreotide, and SSTR 2 (BIM-23190) and SSTR 5 (BIM-23268) specific analogs in 18 somatotroph pituitary adenomas in primary culture.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.